Status:
COMPLETED
A Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066
Lead Sponsor:
Pfizer
Conditions:
Healthy
Eligibility:
MALE
20-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to investigate the pharmacokinetics of single doses of PF-02341066 (150, 250, and 400 mg) in the fasted condition in Japanese healthy male volunteers.
Detailed Description
The purpose of this study is to investigate the pharmacokinetics of single doses of PF-02341066 (150, 250, and 400 mg) in the fasted condition in Japanese healthy male volunteers.
Eligibility Criteria
Inclusion
- Healthy male subjects, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg
Exclusion
- Subjects who are smoking,
- Subjects with evidence of disease,
- Subjects with conditions affecting absorption,
- Subjects with treatment with other investigational drug within 30 days,
- Subjects with history of regular alcohol consumption,
- Subjects with use of prescription, nonprescription drugs and dietary supplement within 28 days,
- Subjects with blood donation of approximately 400 mL within 3 months or 200 mL within 1 month prior to dosing
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT01250730
Start Date
December 1 2010
End Date
January 1 2011
Last Update
November 29 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Hachioji-shi, Tokyo, Japan